Sabine Heitzeneder

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (36)

• c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors.
  Cell reports. Medicine 2026 DOI: 10.1016/j.xcrm.2025.102549
  +Save
• HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
  2025 DOI: 10.1093/neuonc/noaf201.0462
  +Save
• Quantitative surfaceome profiling of high-risk medulloblastoma prioritizes the oncofetal antigen GPC2 for potent CAR-T cell therapy
  2025 DOI: 10.1093/neuonc/noaf201.1473
  +Save
• Engineered CD47 protects T cells for enhanced antitumour immunity.
  Nature 2024 DOI: 10.1038/s41586-024-07443-8
  +Save
• Antigen density quantification of cell-surface immunotherapy targets by flow cytometry: Multi-antigen assay of neuroblastoma bone marrow metastasis.
  STAR protocols 2023 DOI: 10.1016/j.xpro.2023.102709
  +Save
• Identifying tumor-restricted target antigens for adoptive cellular immunotherapy to treat Ewing Sarcoma using multiomic discovery platforms
  2022
  +Save
• Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
  Cell 2022 DOI: 10.1016/j.cell.2022.03.041
  +Save
• Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication
  Nature Medicine 2022 DOI: 10.1038/s41591-021-01625-x
  +Save
• GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
  CANCER CELL 2022 DOI: 10.1016/j.ccell.2021.12-005
  +Save
• Potent activity of CAR T cells targeting the oncofetal protein GPC2 engineered to recognize low antigen density in neuroblastoma.
  2021
  +Save